Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05857969 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Jul 8, 2025, no change to tracked fieldsv8-v9
  2. Phase: Not specified to Phase 1
    • Interventions: Functional Precision Medicine (Device)
    v7
  3. Site contact updatedv6
  4. Site contact updatedv5
  5. Site contact updatedv4
Show 2 earlier versionsHide 2 earlier versions
  1. Site contact updatedv3
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Florida International University
38 trials monitored
See 5 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Acute Myeloid Leukemia (AML)
1,269 trials monitored
See 74 trials at risk
Glioma
1,251 trials monitored
See 88 trials at risk
and 4 more diseases
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Trial Details
NCT Number NCT05857969
Lead Sponsor Florida International University
Collaborators: Nicklaus Children's Hospital f/k/a Miami Children's Hospital, First Ascent Biomedical Inc., National Institute on Minority Health and Health Disparities (NIMHD)
Conditions
(from sponsor)		 Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma +10 more
Related terms Dendritic Cell Sarcoma, Interdigitating, Familial ependymoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 65 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov